Amylyx Pharmaceuticals, Inc.（AMLX）财务数据AMLXAmylyx Pharmaceuticals, Inc.

Evaluating the bottom line, Amylyx Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -74.73%, provide a clear picture of how effectively AMLX converts its operational activities into shareholder value.

In the context of the broader market, AMLX competes directly with industry leaders such as ACAD and TARS. With a market capitalization of $3.53B, it holds a leading position in the sector. When comparing efficiency, AMLX's gross margin of N/A stands against ACAD's 90.81% and TARS's 93.03%. Such benchmarking helps identify whether Amylyx Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Amylyx has shown significant financial challenges, with a negative net income of -43,423,000 in Q2 2026 and a gross margin of 0% in recent quarters, indicating a lack of profitability. However, the company has raised $500 million to support the launch of its avexitide treatment, which could improve its financial outlook.